Division of Hematologic Malignancies and Medical Oncology, NYU Langone Medical Center, 7th Floor, 160 East 34th Street, New York, NY 10016, USA.
Hematol Oncol Clin North Am. 2012 Jun;26(3):671-704, ix. doi: 10.1016/j.hoc.2012.01.006. Epub 2012 Mar 28.
Histone deacetylase inhibitors (HDACI) have allowed pharmacologic manipulation of deregulated genes in cancer cells and have shown single-agent activity against T cell lymphomas, cutaneous T cell lymphomas, mantle cell lymphomas, and Hodgkin disease. The bigger promise of these agents is in enhancing the activity of other targeted therapies. In addition, the effects of HDACI on the immune system and cytokines indicate that HDACI can be useful in the treatment of immune dysfunction underlying tumorigenesis, autoimmune disorders, and graft-versus-host disease. There is also an effort to determine whether class specificity of HDACI has a biologic significance.
组蛋白去乙酰化酶抑制剂（HDACI）可实现对癌细胞中失调基因的药物操控，并对 T 细胞淋巴瘤、皮肤 T 细胞淋巴瘤、套细胞淋巴瘤和霍奇金病具有单药活性。这些药物更大的前景在于增强其他靶向治疗的活性。此外，HDACI 对免疫系统和细胞因子的影响表明，HDACI 可用于治疗肿瘤发生、自身免疫性疾病和移植物抗宿主病所涉及的免疫功能障碍。人们还在努力确定 HDACI 的类别特异性是否具有生物学意义。
